FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

Iovance Biotherapeutics BLA for Melanoma Therapy

Iovance Biotherapeutics files a rolling BLA submission for lifileucel, a tumor infiltrating lymphocyte therapy for treating certain patients with adva...

latest-news-card-1
Medical Devices

Two Final Guides on Covid-19 Device Transition

FDA issues two final guidances on transition plans for Covid-19-related medical devices that were granted emergency use authorizations or were allowed...

latest-news-card-1
Human Drugs

Accelerated Approval Guide Pushes Randomized Trials

Pushing randomized clinical trials, FDA issues a draft guidance entitled Clinical Trial Considerations to Support Accelerated Approval of Oncology The...

latest-news-card-1
Biologics

Cell/Gene Therapy Post-approval Data Meeting

CBER's Office of Therapeutic Products plans a 4/27 public listening meeting to obtain feedback on methods and approaches for capturing post-approval s...

latest-news-card-1

FDA Keeping Close Eye on Social Media Promotion

CDER's Office of Prescription Drug Promotion (OPDP) says it is monitoring very closely the increasing use of social media platforms that promote presc...

latest-news-card-1
Medical Devices

New CDRH Web Page on Diagnostic Data Program

CDRH launches a new Web page to discuss mission-critical priorities of data and technology innovations and provide information and resources on its Di...

latest-news-card-1
Medical Devices

Getinge PMA Approved for Iliac Artery Stent

FDA approves a Getinge PMA for its iCast covered stent system for treating patients with iliac arterial occlusive disease.

latest-news-card-1
Human Drugs

Dose Optimization Info for Combo Drugs Needed: PhRMA

Pharmaceutical Research and Manufacturers of America says a recent FDA draft guidance on oncologic drug development provides limited information on ho...

latest-news-card-1
Human Drugs

Incyte Complete Response on Once-daily Jakafi

FDA issues Incyte a complete response letter for Jakafi (ruxolitinib) extended-release tablets, a JAK1/JAK2 inhibitor for once-daily use in treating c...

latest-news-card-1
Human Drugs

Panel Backs Accelerated OK Consideration of Biogen's ALS Drug

An FDA advisory committee votes 9 to 0 that Biogens amyotrophic lateral sclerosis drug tofersen should be considered for accelerated approval.